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Summary 
Erythropoietin (EPO) is the principal growth factor reg- 
ulating the production of circulating erythrocytes. We 
introduced null mutations into both Epo and the EPO 
receptor (EpoR) gene. Both heterozygotes appeared 
normal. Homozygous animals exhibited reduced prim- 
itive erythropoiesis and died around embryonic day 
13, owing to failure of definitive fetal liver erythropoie- 
sis. Both types of mutations exhibited identical pheno- 
types, indicating that EPO and the EPOR are crucial 
for definitive erythropoiesis in vivo and that no other 
ligands or receptors can replace them. Committed ery- 
throid BFU-E and CFU-E progenitors were present in 
both homozygous fetal livers. Thus, neither EPO nor 
the EPOR is required for erythroid lineage commitment 
or for the proliferation and differentiation of BFU-E to 
CFU-E progenitors. EPO and the EPOR are crucial in 
vivo for the proliferation and sunrival of CFU-E progen- 
itors and their irreversible terminal differentiation. 
Introduction 
Blood cells are formed continuously from a small group 
of pluripotent stem cells that generate progenitors commit- 
ted to one or a few hematopoietic lineages. Control of 
these differentiation pathways is determined, in part, 
through specific growth factors binding to their cognate 
receptor(s) (Metcalf, 1989). Erythropoietin, a 34 kDa glyco- 
protein hormone, is the crucial growth factor that promotes 
the survival, proliferation, and differentiation of mamma- 
lian erythroid progenitor cells (Krantz, 1991). EPO is re- 
markably specific for erythroid progenitors, owing to the 
tissue-specific expression of its receptor (EPOR) (D’An- 
drea et al., 1989). 
Within the mammalian embryo, erythropoiesis occurs 
initially in the yolk sac blood islands (primitive erythropoie- 
sis) and then shifts to the fetal liver, spleen, and eventually 
to the bone marrow (definitive erythropoiesis). EPO is pro- 
duced primarily by the fetal liver during midgestation and 
by the kidney from late gestation to adulthood (Koury et 
al., 1988a, 1988b, 1991). The source of EPO prior to the 
fetal liver stage and the function of EPO in primitive eryth- 
ropoiesis are not clear. Maternal EPO might support fetal 
erythropoiesis via transfer across the placenta (Koury et 
al., 1988a); EPOR has been detected in placenta (Anag- 
nostou et al., 1994), where it may function in transepithelial 
transport of EPO. 
Committed erythroid progenitor cells that specifically re- 
spond to EPO are detected by the formation of discrete 
erythroid colonies following in vitro culture in plasma clots 
or methylcellulose and are termed the colony-forming unit- 
erythroid (CFU-E) and the burst-forming unit-erythroid 
(BFU-E) (Gregory and Eaves, 1977; Gregory and Eaves, 
1978). As demonstrated by thymidine suicide experi- 
ments, the CFU-E is a rapid dividing cell that is highly 
responsive to low concentrations of EPO and gives rise 
to erythroblast colonies of 8-49 cells in 7 days (human) 
or of 8-64 cells in 2 days (mouse). The BFU-E is a more 
immature cell that divides less frequently. This cell re- 
quires EPO as well as other growth factors (Emerson et 
al., 1985), such as interleukin-3 (IL-3) granulocytelmacro- 
phage colony-stimulating factor (GM-CSF), and stem cell 
factor (SCF) to develop into grouped clusters of erythro- 
blasts or larger colonies (bursts) of greater than 500 eryth- 
roblasts by 15 days (human) or 7-10 days (mouse) in cul- 
ture (Gregory and Eaves, 1977, 1978). Development from 
the earliest BFU-E to the latest CFU-E is a continuous 
process, with an intermediate progenitor often termed the 
mature BFU-E (Gregory and Eaves, 1977,1978). The sen- 
sitivityof these progenitors to EPO is transient. Beyond the 
late basophilic erythroblast stage, the level of the EPOR 
drops, and the cells are no longer dependent on EPO for 
continued maturation (Koury and Bondurant, 1988). While 
EPO is thought to be required for proliferation from BFU-E 
to CFU-E and subsequent proliferation of the CFU-Es, the 
role of EPO in regulating erythroid differentiation is less 
defined. 
We are interested in several aspects of the in vivo func- 
tion of EPO and the EPOR. Specifically, we want to know 
whether maternal EPO can support fetal erythropoiesis; 
whether EPO plays a similar role in primitive and definitive 
erythropoiesis; whether EPO is an essential factor in de- 
termining the commitment of cells to the erythroid lineage; 
and whether EPO is crucial for proliferation and differentia- 
tion of some or all types of erythroid progenitor cells. To 
address these questions, a defined in vivo system is 
needed. We have generated mouse strains carrying null 
mutations in the Epo or EpoR genes by gene targeting in 
embryonic stem cells. We show that heterozygous mice 
lacking one allele of the Epo or EpoR genes are viable 
and fertile and have normal erythrocytes and leukocytes. 
Homozygous mice, however, die by embryonic days 13- 
15 (E13-E15) with severe anemia. By culturing fetal livers 
from both types of homozygous embryos, we showed that 
BFU-E and CFU-E progenitorswere present. Thus, neither 
EPO nor the EPOR is required for erythroid lineage com- 
mitment or for the proliferation and differentiation of BFU-E 
to CFU-E progenitors. Our results reveal an essential role 
for EPO in regulating definitive erythropoiesis by control- 
ling processes such as proliferation, survival, and irrevers- 
ible terminal differentiation of the late progenitors (CFU-E). 
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Results clones isolated, homologous recombination occurred at a 
frequency of 13.5%. 
Disruption of the Murine Epo and EpoR Genes 
The murine Epo gene is encoded by five exons within 2.7 
kb of genomic DNA (McDonald et al., 1986; Shoemaker 
and Mitsock, 1986). The translational start site (ATG) is 
located in the first exon. We constructed a replacement- 
type targeting vector, pEpo-Ml, that contains 2.5 kb up 
stream and 5.0 kb downstream flanking sequences of the 
Epo gene, and the PGKneopA cassette for positive selec- 
tion (Figure 1A). Exons 2-5 were completely deleted so 
that no EPO protein could be produced from the mutant 
allele. After electroporation and drug selection, G418- 
resistant (G418’) clones from embryonic stem (ES) cells 
were isolated (see Experimental Procedures). DNAs from 
individual cloneswere prepared and digested with EcoRV. 
After gel separation, filters were hybridized with an exter- 
nal probe from the 3’flanking region, as indicated in Figure 
1A. A 10.0 kb band corresponding to the targeted allele 
was detected in 10.8% of ES clones isolated (data not 
shown). 
The EpoR gene is encoded by eight exons with the trans- 
membrane domain encoded by exon 6. The minimum pro- 
moter is located 0.5 kb upstream of the transcription initia- 
tion site (Youssoufian et al., 1993). To silence the EpoR 
gene completely, we constructed the pEpoR-Ml plasmid, 
in which a 4.7 kb BarnHI-Xbal fragment from the EpoR 
locus, including 1.6 kb from the 5’ flanking region and 
exons l-6, was deleted and replaced with PGKneopA for 
positive selection (Figure 1B). Among 400 G418’ ES 
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Figure 1, Epo and EpoR Genomic Maps and Targeting Vectors 
(A) A restriction map of the genomic region containing the Epo gene 
is shown in the middle with the exons numbered. The targeting vector 
pEpo-Ml and the location of the PGKneopA cassette are shown at 
the top. By EcoRV digestion of genomic DNA, a 15.5 kb or a 10 kb 
band is detected from the wild-type or targeted allele, respectively, 
through use of an external probe located at the 3’ end of the gene. 
(B) A restriction map of the EpoR locus containing eight exons is shown 
in the middle. At the top, the targeting vector and the location of the 
PGKneopA cassette are indicated. An external probe derived from the 
5’ end of the gene, which hybridizes to a 9.5 kb and a 4.2 kb band, 
respectively, from the wild-type and targeted allele, is used to screen 
colonies and to determine the genotypes of the mice. 
Epo-‘- and EpoW- Mice Are Embryonic Lethal 
Targeted ES clones carrying null mutations in the fpo or 
EpoR genes were injected into C57BU6 or BALBlc blasto- 
cysts, and the resulting chimeric mice were backcrossed. 
Germline transmission of the mutant allele was detected 
by Southern blot analysis of tail DNA from Fl offspring. 
Four and two independently isolated ES clones transmit- 
ted the mutant Epo and EpoR alleles, respectively, to the 
germline. 
Heterozygotes carrying deletions in either the fpo or 
EpoR genes appeared normal and were viable and fertile. 
The levels of blood hemoglobin, hematocrit, erythrocytes, 
and leukocytes and the protein composition of plasma 
were within normal ranges (data not shown). Heterozygotes 
derived from independent ES clones were then intercrossed 
to determine whether mice homozygous for either muta- 
tion were viable. No mice homozygous for the fpo or EpoR 
null mutation were found at 3 weeks of age; since no post- 
natal lethality was observed, the homozygous Epo-I- or 
@OR-‘- mice were embryonic lethal. Examination of em- 
bryos at successive stages of embryonic development re- 
vealed that homozygous Epo-‘- or EpoR-‘- embryos died 
between days 13 and 15 of gestation (data not shown). 
No difference was seen in mice derived from different ES 
clones or under different genetic backgrounds. 
Definitive Erythropoiesis in Epo-I- or EpoR-‘- Fetal 
Liver Is Completely Impaired 
Gross examination of mutant embryos revealed that the 
most dramatic consequence of the Epo and EpoR muta- 
tions was severe anemia. No significant differences were 
observed between wild-type and heterozygous littermates 
(data not shown). Homozygous embryos, however, devel- 
oped normally until day 13 but appeared very pale; no red 
coloring characteristic of the normal fetal liver (Figure 2A) 
could be seen in the fpo-‘- (Figure 28) or fpoR+'- (data not 
shown) embryos. Placentas surrounding the homozygous 
embryos were of normal size but had fewer erythrocytes. 
Fetal livers were four to five times smaller than those in the 
normal littermates and were very pale (data not shown), 
indicating a significant reduction in erythrocyte production. 
Histological examination of fetal liver sections obtained 
from wild-type and homozygous mutants allowed the eval- 
uation and comparison of erythropoieticfoci within the liver 
parenchyma. Erythropoietic islands were numerous in the 
livers from wild-type (Figure 3A, arrows) or heterozygous 
(data not shown) animals but were not identifiable in livers 
from fpo-'- embryos (Figure 38). In the wild-type or hetero- 
zygous fetal livers, erythroid cells at all stages of differenti- 
ation could be seen. In contrast, the only erythroid cells 
seen in the homozygous fetal livers were large erythro- 
blasts (see below). All liver sections also showed yolk sac- 
derived erythrocytes with characteristic abundant eosin- 
ophilic cytoplasm and large nuclei (Figures 3A and 38, 
arrowheads). Many pycnotic nuclei, characteristicof apop- 
totic cells, were seen in liver sections from the fpo-'- em- 
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Figure 2. Phenotypic Comparison of El3 Littermates from Epo+‘- 
Parents 
The wild-type mouse is shown on the left (A), and the homozygous 
mutant littermate is at the right (B). The mutant mouse appears to 
be grossly normal except for the significant reduction of circulating 
erythrocytes and pale coloring of the liver. 
bryos (Figure 3B, inset, small arrows), but fewwere visible 
in fetal livers from wild-type and Epo+‘- embryos. Confirm- 
ing these results, cytospin preparations from livers of nor- 
mal (Figure 3C) and homozygous (Figure 3D) mice were 
analyzed by Giemsa staining. Erythropoietic cells at all 
stagesofdifferentiation, including many fetal liver-derived 
nonnucleated erythrocytes (N) and few yolk sac-derived 
nucleated erythrocytes (Y), were seen in the wild-type liver 
preparation (Figure 3C), while only proerythroblasts (E) 
and yolk sac-derived nucleated erythrocytes (not shown) 
were identifiable in the preparation from the Epo-‘- homo- 
zygotes (Figure 3D). The same results were obtained by 
analyzing the fetal livers from the EpoR? embryos, com- 
pared with those from the heterozygous and wild-type em- 
bryos (data not shown). These results indicate that EPO 
and EPOR are essential for controlling production of defini- 
tive erythrocytes in fetal liver. 
Fetal Livers from &JO-‘- Embryos Have BFU-E 
and CFU-E Progenitors 
To determine at which stage of erythropoiesis EPO plays 
a crucial role, we quantified erythroid progenitors in fetal 
livers from Epo-‘- embryos. Consistent with the anatomical 
and histological analyses, livers from fpo-‘- fetuses had 
significantly decreased numbers of nucleated cells: an ap- 
proximately 6-fold and 17-fold reduction at El25 and 
E13.5, respectively, compared with wild-type and hetero- 
zygous littermates (Figure 4A). 
If the Epo-‘- fetal livers do contain CFU-Es and BFU-Es, 
we should be able to detect benzidine-positive colonies 
after 2-3 days (for CFU-E) or 7-10 days (for BFU-E) of 
cultivation when exogenous EPO is supplemented, since 
these progenitors express the EPOR on their surface. For 
this purpose, single cell suspensions were prepared and 
plated in methylcellulose culture supplemented with a 
cocktail of growth factors including EPO, and benzidine- 
positive colonies were counted. As shown in Figures 48 
and 4C, fetal livers from &IO-‘- embryos contained ery- 
throid progenitors, and the relative number of both CFU-E 
and BFU-E progenitors per 1 O5 nucleated cells was signifi- 
cantly increased over that in the wild-type and heterozy- 
gous fetal livers (Figures 4B and 4C). These results sug- 
gested that the homozygous fetal livers were enriched in 
progenitor cells. Cytospin preparations of cloned BFU-Es 
showed only adult-type definitive erythroid cells (data not 
shown). The numbers of CFU-granulocytelmacrophage 
and CFU-megakaryocyte in cultures from homozygous 
@o-l- fetal livers were normal (data not shown), sug- 
gesting that the function of EPO in vivo is restricted to the 
erythroid lineage. Interestingly, in the control fetal livers, 
progenitor cells undergo rapid proliferation and differentia- 
tion to generate more mature forms of erythroid cells (see 
Figure 3C), and the number of nucleated cells per fetal 
liver increased 4-fold from El25 to E13.5 (Figure 4A). On 
the other hand, the relative number of progenitors de- 
creases with embryonic development: a 3-fold and a 2-fold 
reduction in the numbers of CFU-E and BFU-E per lo5 
nucleated cells, respectively, were observed (Figures 4B 
and 4C). In contrast, no significant increase in the number 
of nucleated cells was observed in livers from Epo-‘- em- 
bryos, suggesting that, in the absence of EPO, fetal liver 
cells either become growth-arrested or undergo apoptosis 
(Figure 4A). Interestingly, the number of BFU-E progeni- 
tors in homozygous fetal livers stayed constant from El 2.5 
to E13.5, while the number of CFU-Es decreased almost 
2-fold (Figures 48 and 4C), indicating that in the absence 
of EPO some of the CFU-Es underwent apoptosis, as sug- 
gested by the histologic analysis in Figure 3B. No differ- 
ences were seen in either the size or the degree of hemo- 
globinization among erythroid colonies derived from the 
Epo-‘- homozygotes or their wild-type or heterozygous lit- 
termates (data not shown). 
Maternal EPO Cannot Support 
Fetal Erythropoiesis 
It has been suggested that maternal EPO could cross the 
placental barrier and support fetal erythropoiesis (Koury et 
al., 1988a). In particular, in the EPO-‘- embryos the amount 
might be sufficient to allow generation of BFU-Es and 
CFU-Es in the fetal liver yet insufficient to support CFU-E 
differentiation. However, higher concentrations of EPO (3 
U/ml) are required for in vitro differentiation of the earlier 
BFU-Es than for the later CFU-Es (0.03 U/ml) (Gregory 
and Eaves, 1978). The facts that Epo-‘- embryos died at 
El 3-El5 gestation stages, right after the switch from prim- 
itive to definitive erythropoiesis, and that no differences 
were seen between fpo-‘- and EpoR-I- mice, also sug- 
gested that maternal sources of EPO cannot substantially 
affect the definitive erythropoiesis in either fpo-‘- or wild- 
type embryos. 
To confirm that maternal EPO did not affect fetal erythro- 
poiesis, Epo+‘- heterozygous females, O-7 days after de- 
tection of the vaginal plug, were injected daily with 3000 
U/kg recombinant murine EPO (rmEP0). An approxi- 
mately 20% increase in hematocrit was detected in these 
females after 8 days of injection (data not shown). How- 
ever, no Epo-‘- homozygotes were found in 83 embryos 
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Figure 3. Liver Section and Liver Cell Cytospin 
Preparations from wild-type and Epo”- mutant fetuses. 
(A) Hematoxylin- and eosin-stained section of liver from a El3 wild-type fetus. The liver contains numerous islands of erythropoietic cells (arrows) 
and some yolk sac-derived nucleated erythrocytes (arrow heads). Scale bar, 25 nm. 
(6) Liver preparation from an El3 fpo-‘- mutant fetus; hematoxylin and eosin staining. Liver cells are large. Nucleated yolk sac-derived erythrocytes 
(arrow heads) are prominent in the absence of significant definitive erythropoiesis. Apoptotic figures are seen (see inset, small arrows). Same 
magnification as in (A). 
(C) Liver cytospin preparation from a wild-type El3 fetus; Giemsa staining. Numerous erythropoietic cells in all stages of differentiation are seen, 
including proerythroblasts (E), basophilic erythroblasts (S), polychromatic erythroblasts (P), orthochromatic erythroblasts (0), and nonnucleated 
erythrocytes (N). Yolk sac-derived nucleated erythrocytes were also seen (Y). Scale bar, 10 Fm. 
(D) Liver cytospin preparation from a El3 Epo-‘+ mutant fetus; Giemsa staining. Proerythroblasts (E) are prominent with noticeable absence of 
cells at later stages of differentiation; yolk sac-derived nucleated erythrocytes are occasionally seen (data not shown). Same magnification as 
in (C). 
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Figure 4. Erythroid Progenitor Cells in Normal and iZoo-‘- Mutant Fetal 
Livers 
(A) Total number of nucleated cells per fetal liver. 
(B) Number of CFU-E detected after 2 days of cultivation in a-methyl- 
cellulose supplemented with a cocktail of growth factors 
(C) Number of BFU-E observed after 7-10 days of cultivation in c-methyl- 
cellulose medium supplemented with a cocktail of growth factors. 
CFU-E and BFU-E numbers are expressed per IO5 nucleated fetal 
liver cells. The error bars represent one standard deviation of the 
mean. The numbers at the top of each error bar indicate the number 
of fetuses analyzed. 
examined after El5 of gestation, and no improvement in 
erythropoiesis was observed in the homozygous embryos 
at El 2-El3 gestation stages (data not shown). These re- 
sults strongly suggest that maternal EPO cannot support 
fetal erythropoiesis and that the development of BFU-E 
and CFU-E progenitors in the Epo-‘- fetal liver is not due 
to maternal EPO. 
EpoRP- Fetal Livers Also Have BFU-E 
and CFU-E Progenitors 
Definitive evidence that neither EPO nor the EPOR is re- 
quired for the generation of BFU-E and CFU-E progenitors 
came from an analysis of homozygous EpoRV embryos. 
Direct detection of CFU-Es and BFU-Es in fetal livers from 
the Epo-‘- embryos should not be possible by culture in 
methylcellulose, since EPO, acting through the EPOR, 
is essential for the production of both types of colonies. 
Indeed, when fetal liver cells from EpoR-‘- embryos were 
cultured with EPO, no CFU-Es or BFU-Es could be seen 
(data not shown). Low levels of CFU-Es and BFU-Es, how- 
ever, were detected when cultures were supplemented 
with a cocktail of growth factors including EPO (Figure 5, 
uninfected). Therefore, we infected fetal liver cells from 
E12.5 EpoR-‘- embryos with a recombinant retrovirus ex- 
pressing the wild-type EpoR (Pharr et al., 1993), and the 
cells were subsequently placed in methylcellulose culture 
without added growth factors or were supplemented with 
a cocktail of growth factors including EPO. In the absence 
of added growth factors, no CFU-Es and BFU-Es were 
detected after retroviral infection (data not shown). In the 
presence of the cocktail of growth factors, the number of 
erythroid progenitors per lo5 nucleated cells was about 
the same as that in normal fetal livers (Figure 5). Since 
fpo-‘- and EpoR-‘- embryos died at the same develop- 
mental stage and their fetal livers contained similar num- 
bers of nucleated cells (data not shown), we assume that 
the total number of progenitor cells in EpoRV fetal livers 
A CFU-E 
Figure 5. Erythroid Progenitor Cells in El 2.5 Normal and EpoR-‘- Mu- 
tant Fetal Livers 
The cells from El25 @OR-‘- livers were incubated with or without 
SFFVEpoR for 2-3 hr on ice. Heterozygous and wild-type fetal liver 
cells were also incubated under the same conditions but without virus. 
After infection, the cells were washed and then plated in methylcellu- 
lose; benzidine-positive colonies were counted after 2 days (CFU-E, 
[A]) and 7-10 days (BFU-E, [B]) of cultivation. All values are expressed 
per IO5 nucleated fetal liver cells. The error bars represent one stan- 
dard deviation of the mean. 
is very similar to that in Epo-‘- fetal livers. On this basis, 
we estimate that the infection efficiencies for BFU-E and 
CFU-E progenitor cells were 40% and 53%, respectively. 
Thus, the generation of BFU-E and CFU-E progenitors in 
mouse fetal liver proceeds independently of the produc- 
tion and expression of fpo or EpoR, and the essential 
function of EPO and EPOR in vivo is to enable the CFU-E 
progenitors to survive and to trigger their proliferation and 
then irreversible terminal differentiation. 
Primitive Erythropoiesis in the Epo-l- and EpoR-‘- 
Yolk Sac Is Partially Impaired 
In early embryogenesis (E7-El l), the yolk sac is the first 
site of erythropoiesis. By E12, however, the major site of 
erythropoiesis has shifted from the yolk sac to the liver. 
The fact that Epo-‘- and EpoR-‘- mutants developed nor- 
mally and survived to El 3 suggested that primitive erythro- 
poiesis at the yolk sac stage might be normal. However, 
both Epo-‘- (data not shown) and EpoRV embryos at ElO- 
El 1 of gestation were very pale (Figure 6A, right), allowing 
unequivocal identification of homozygous mutants, Blood 
vessels in the yolk sac of EpoR-‘- embryos had many fewer 
erythrocytes (Figure 6A, right) than did the normal em- 
bryos (Figure 6A, left). Peripheral blood was collected from 
phenotypically normal and homozygous Epc- or fpoR’- 
embryos at El l-El2 of gestation, and total blood cells 
were counted. There was a 5- to lo-fold reduction in the 
number of blood cells in either fpo-‘- or EpoR-‘- mutants 
as compared with that in wild-type or heterozygous lit- 
termates (data not shown). Importantly, some primitive 
erythrocytes were present in the yolk sac surrounding the 
EpoR-‘- (Figure 6C) and fpo-‘- (data not shown) embryos, 
though many fewer than in normal embryos (Figure 6B). 
Thus, a low level of EPO and EPOR-independent erythro- 
poiesis in the yolk sac allows homozygous Epo-I- and 
EpoRV embryos to develop and survive from E7 to El3 
of gestation. 
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Discussion 
In this study, we generated mouse strains in which either 
the endogenous Epo or the EpoR gene was inactivated 
via homologous recombination in ES cells. Our results 
reveal a pivotal role for EPO and EPOR in erythropoiesis. 
Yolk sac hematopoiesis is significantly reduced and leads 
to severe anemia. Definitive erythropoiesis, which begins 
in the fetal liver and thereafter in the spleen and bone 
marrow of adults (Figure 7) is completely impaired, re- 
sulting in embryonic lethality by E13-E15. The deficiency 
in erythropoiesis is not at the stem cell or progenitor cell 
level, since both BFU-E and CFU-E progenitors are pres- 
ent in the fetal livers derived from both fpo-I- and @ O R ’- 
mice. Our data indicate that the major function of EPO is 
to trigger proliferation and then irreversible terminal differ- 
entiation of the committed late erythroid CFU-E progeni- 
tors. EPO may also act to prevent apoptosis of CFU-Es. 
EPO Does Not Cross the Placenta into the Fetus 
Whether a maternal source of EPO can support fetal eryth- 
ropoiesis is controversial. In sheep and monkeys, adminis- 
tration of EPO to pregnant females causes significant in- 
Figure 6. Whole Embryos and Sections of the 
Yolk Sac from Wild-Type and EpoR-‘- Mice 
(A) Phenotypic comparison of El1 wild-type 
(left) and EpoR-‘- (right) embryos. The embryos 
are within the yolk sac; the mutant yolk sac 
appears very pale with significant reduction in 
circulating erythrocytes. 
(6) Yolk sac section from an El 1 wild-type em- 
bryo; hematoxylin and eosin staining. Yolk 
sac-derived nucleated erythrocytesfill the ves- 
sels (arrows). Scale bar, 25 pm. 
(C)Yolk sac section from a El 1 EpoR- mutant 
embryo; hematoxylin and eosin staining. Most 
of the vessels are empty. Yolk sac-derived 
erythrocytes are seen occasionally (arrows). 
Same magnification as in (6). 
creases in the level of circulating maternal EPO and in 
maternal erythropoiesis (Zanjani et al., 1993). However, 
there was no increase in the level of fetal plasma EPO or 
in fetal reticulocyte production unless EPO was directly 
injected into the fetus, suggesting that the fetal erythrocyte 
production is not affected by maternal levels of EPO (Zan- 
jani et al., 1993). One study using mice demonstrated the 
transferof maternallyadministrated [lZSI]EPO intothefetus 
(Koury et al., 1988a). Although the small size of the mouse 
fetus and the short gestation period in mice did not permit 
direct assessment of the physiological significance of 
transplacental transfer of EPO, this finding raises the pos- 
sibility that EPO from a maternal source may be involved 
in the regulation of erythropoiesis in the fetus. 
Thisquestion wasdirectlyaddressed here inourstudyof 
@o-‘-and @OR-‘- mice. If significant amountsof maternal 
EPO do cross the placenta into the fetus, we would expect 
&JO-‘- mice to survive until birth. If maternal EPO cannot 
support fetal erythropoiesis, then Epo-‘- mice, like EpoR+ 
mice, should die during embryogenesis. No fpo-‘- and 
EpoR-‘- homozygous mice survived to birth, and both 
fpo-‘- and EpoR-‘- mice died at the same period of gesta- 
tion with severe anemia. Administration of high doses of 
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Figure 7. Growth Factors Involved in Regulating Murine Erythropoie- 
sis In Vivo 
SCF and its receptor KIT are important for the proliferation and differen- 
tiation of committed erythroid progenitors from the BFU-E to the CFU-E 
stage. EPO and EPOR are crucial for the survival of the late CFU-E 
progenitors, their irreversible differentiation, or both. EPO and EPOR 
are essential for definitive erythropoiesis in the fetal liver and have a 
partial role in controlling primitive erythropoiesis in the yolk sac. 
rmEP0 to pregnant Epo+‘- females significantly increased 
the hematocrit of the mothers but had no effect on the 
erythropoiesis in the livers of Epo-I- fetuses or on the sur- 
vival of the homozygous embryos. Thus, our results pro- 
vide definitive physiological and functional evidence that, 
in mice, maternal EPO cannot cross the placenta and reg- 
ulate fetal erythropoiesis. 
The Roles of EPO and the EPOR in Primitive 
and Definitive Erythropoiesis 
In the developing mouse embryos, the yolk sac is the origi- 
nal site of hematopoiesis, with the first stem cell colony- 
forming units (CFU-S) appearing at approximately E7 of 
gestation (Moore and Metcalf, 1970). By E12, the fetal 
liver becomes the major hematopoietic center. Fetal liver 
erythropoiesis and yolk sac erythropoiesis are distinct in 
several ways. In the blood islands of the yolk sac, erythro- 
cytes mature as a cohort in a somewhat synchronousfash- 
ion, which is quite different from the asynchronous differ- 
entiation that occurs in the fetal liver (Tavassoli and Yoffey, 
1983). Yolk sac erythropoiesis normally generates only 
large nucleated erythrocytes that synthesize embryonic 
hemoglobin. Fetal liver erythropoiesis, in contrast, pro- 
duces nonnucleated erythrocytes that express adult he- 
moglobin. Some experiments have demonstrated that the 
fetal liver and yolk sac erythropoiesis differ in their respon- 
siveness to EPO (Cole and Paul, 1966). 
In @o-j- and EpoR-‘- embryos, definitive erythropoiesis 
was completely blocked, suggesting that EPO plays a criti- 
cal role in regulating the erythrocyte production in the fetal 
liver. Primitive erythropoiesis in the yolksacwas, however, 
only partially impaired, with a 5 to IO-fold reduction in 
erythrocyte production. A small number of primitive eryth- 
rocytes are produced in the complete absence of either 
EPO or the EPOR, indicating that some of the erythroid 
progenitor cells in the yolk sac are able to proliferate and 
differentiate independent of either EPO or EPOR. Thus, 
the low level of CFU-E and BFU-E colonies detected in 
the @OR-‘- fetal liver prior to retroviral infection (Figure 
5, uninfected) could be due to this small group of yolk sac- 
derived erythroid progenitors that migrated to the fetal liver 
after the blood circulation started at E9 of gestation. These 
results are not likely to be due to the leakiness of the 
knock-out mutations, since functional proteins are not 
likely to be generated from the mutant alleles (Figure 1). 
On the other hand, our results raise the very interesting 
possibility that two distinct populations of erythroid pro- 
genitors are present in the murine yolk sac, one being 
EPO- and EPOR-dependent and the other EPO- and 
EPOR-independent. 
EPO and EPOR Are Not Required for the Formation 
of Definitive Erythroid Progenitor Cells 
The control of erythropoiesis by EPO has been intensively 
studied both in vivo and in cell culture. Experimental ma- 
nipulation of EPO levels in animals, either through the 
induction of anemia that stimulates the endogenous EPO 
production and increases circulating levels of erythro- 
cytes, or through direct administration of EPO, resulted 
in a significant change in the number of CFU-Es, but only 
small and variable effects in the number of BFU-Es in 
the bone marrow (Hara and Ogawa, 1977; Peschle et al., 
1979). These studies suggest that EPO induces the forma- 
tion of CFU-Es from BFU-E progenitors. Administration 
of large amounts of EPO in humans led to a significant 
increase in the number of BFU-Es in the bone marrow and 
in the percentage of the BFU-Es active in DNA synthesis 
(Dessypris et al., 1988). Importantly, we do not know 
whether these effects were due to a direct action of EPO 
to stimulate the development of BFU-Es and CFU-Es from 
earlier progenitors or, alternatively, to support their sur- 
vival. In addition, the effects of EPO may be indirect, possi- 
bly through the stimulation of production of other hemato- 
poietic growth factors or through nonspecific stimulation 
of accessory or stromal cells. 
The formation of BFU-Es in cell culture is affected by 
a number of growth factors besides EPO, including SCF, 
IL-3, and GM-CSF (Emerson et al., 1985). We do not know 
how these factors function cooperatively with EPO in vivo 
in controlling proliferation and differentiation of erythroid 
progenitors. The level of EPO responsiveness correlates 
well with the amount of EPOR expressed on the surface 
of the progenitor cells. The human early BFU-Es have little 
or no EPOR on their surface and are not responsive to 
EPO. After 48-72 hr of growth in the presence of IL-3, 
GM-CSF, or SCF, mature (also called late) BFU-Es de- 
velop; they express low levels of EpoR and are weakly 
responsive to EPO (Sawada et al., 1988, 1990). After an- 
other 4-5 days in culture, these cells give rise to a number 
of CFU-Es that are highly responsive to EPO (Gregory and 
Eaves, 1977) and express approximately 1000 EPORs on 
their surface (Sawada et al., 1988). On the basis of these 
experiments, EPO was thought to function with other 
growth factors, such as IL-3, GM-CSF, and SCF, in control- 
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ling the proliferation and differentiation of BFU-E progeni- 
tors to CFU-Es. EPO is clearly the crucial growth factor 
for the subsequent proliferation and differentiation of 
CFU-Es. 
Molecular genetic analysis of mice with a null mutation 
in the gene encoding GM-CSF has indicated that GM-CSF 
is not crucial for erythropoiesis, or that other factors can 
compensate for its function (Dranoff et al., 1994). SCF, 
however, is crucial for the development of BFU-E progeni- 
tor cells to the CFU-E stage (Figure 7), since mice lacking 
SCF (SI mutants) or its receptor KIT (W mutants) exhibit 
a significant reduction of CFU-E progenitors in their fetal 
liver and suffer from severe anemia (Nocka et al., 1989). 
Since the survival and proliferation of the CFU-E progeni- 
tors depends absolutely on EPO, these results suggest 
that the committed erythroid progenitors cannot proliferate 
or mature further unless both the KIT and the EPOR signal 
transduction pathwaysarefunctional. While KITbindssev- 
eral intracellular signal transduction proteins, such as 
Pl3K and PLCyl, we do not know how it contributes to 
proliferation and differentiation of the erythroid cells. 
Recently, we demonstrated (Wu et al., 1995) that SCF 
could replace EPO in supporting the growth and survival 
of HCD57 cells, an EPO-dependent erythroid cell line. In- 
terestingly, SCF supported the proliferation of 32D cells 
expressing KIT only if they also expressed EpoR. In 
HCD57 cells, KIT and the EPOR were complexed to- 
gether, and SCF rapidly induced tyrosine phosphorylation 
of the EPOR. These results suggested that KIT may acti- 
vate the EPOlEPOR signal transduction pathway via tyro- 
sine phosphorylation of the EPOR and, in turn, the acti- 
vated EPOR could induce the further proliferation and 
maturation of committed erythroid progenitor cells. Since 
fetal livers from EPOR-‘- embryos contain CFU-Es and 
can be rescued by expression of recombinant EpoR, we 
suggest that interaction of the KIT and EPOR at or around 
the CFU-E stage may be particularly important for trig- 
gering subsequent cell proliferation, differentiation, or 
both. 
In summary, we showed that in the absence of EPO or 
EPOR, BFU-E and CFU-E progenitors developed normally 
in vivo but failed to undergo terminal differentiation to form 
mature erythrocytes. These results suggest that neither 
EPO nor the EPOR is required for erythroid lineage com- 
mitment or for the proliferation and differentiation of BFU-E 
to CFU-E progenitors. EPO and the EPOR are crucial in 
vivo for proliferation of CFU-E progenitors and for their 
survival and irreversible terminal differentiation into eryth- 
rocytes (Figure 7). Our results also indicate that there are 
no other ligands or receptors that can replace EPO and 
the EPOR in controlling definitive erythropoiesis. How- 
ever, low levels of EPO- and EPOR-independent erythro- 
poiesis do occur in primitive erythropoiesis at the yolk sac 
stage, suggesting that other mechanisms may play a criti- 
cal role. 
Experimental Procedures 
Construction of Targeting Vectors 
Genomic DNA clones corresponding to the Epo or EpoR locus were 
isolated from a 129(Jl) genomic library (Wu et al., 1994). 
pEpo-Ml 
The targeting vector pEpo-Ml was constructed by first inserting a 2.5 
kb Pstl-Pstl fragment from the 5’end of the Epo gene into a Bluescript 
vector, forming pEpo-Ml-S: Then a 1.8 kb EcoRI-Hindlll fragment 
from the plasmid pGEM7(KJl)R (Rudnicki et al., 1992) containing 
PGKneopAsequenceswas inserted into the EcoRl and Hindlll sitesof 
the pEPO-Ml-5’vector, forming pEpo-Ml -neo. Finally, a5.0 kb Hindlll- 
Kpnl fragment from the 3’ region of the Epo gene was inserted into 
the Hindlll and Kpnl sites of the pEpo-Ml-neo vector (Figure 1A). 
pEpoRM1 
The targeting vector pEpoR-Ml was constructed by first replacing a 
Bglll-BamHI fragment in the plasmid pGEM7(KJl)R (Rudnicki et al., 
1992) with a 4 kb Sall-BamHI fragment derived from the 5’end of the 
EpoR locus, yielding pEpoR-Ml-S: and then inserting the 2.7 kb Xbal- 
EcoRI* (site in the polylinker) fragment derived from the 3’end of the 
EpoR gene into the Xbal and EcoRl sites of the plasmid pEpoR-Ml-S’ 
(Figure 1B). 
Electroporation, Selection of ES Clones, 
and Southern Blot Analysis 
Jl ES cells were cultured essentially as described (Li et al., 1992). 
To introduce the targeting vector into the endogenous gene, 25 Kg of 
pEpo-Ml or pEpoR-Ml plasmid was linearized at the Notl or Sall site, 
respectively, and electroporated into 1 x 10’ Jl ES cells in a volume 
of 0.8 ml at 400 V and 25 PF by use of a Bio-Rad Gene Pulser. After 
24 hr of culture, the medium was supplemented with 400 wglml G418 
(GIBCO BRL), and 400 ES clones from each electroporation were 
isolated after 7-l 0 days of selection. Individual clones were expanded, 
and genomic DNAs were prepared as described (Laird et al., 1991). 
DNAs were digested with EcoRV and resolved on a 0.7% agarose 
gel. After transferring, filters were hybridized with 32P-labeled probes, 
as indicated in Figure 1. 
Generation of Germline Chimeras 
ES clones containing the null mutations were injected into BALB/c or 
C57BU6 embryos. Chimeric mice were backcrossed to BALBlc or 
C57BU6 mice, and germline transmission of the mutant allele was 
detected by Southern blot analysis of tail DNA from Fl offspring with 
agouti coat color. 
Histological Analysis of Embryos 
Embryos were dissected free of uterine muscle and decidua, and the 
placenta and yolk sac were saved for genotyping. For histology, the 
embryos were placed in 10% buffered formalin for 24-48 hr and then 
in successive ethanol and xylene baths and finally embedded in Para- 
plast Plus (Oxford) with an Autotechnicon mono embedder (Tech- 
nicon). Embryos were sectioned by using a Reichert-Jung microtome 
and stained with hematoxylin and eosin. 
Progenitor Cell Assays 
Individual fetal livers were dissected free in Iscove’s modified Dulbec- 
co’s medium (IMDM), disaggregated into single cell suspensions, 
passed through a Cell Strainer (70 Nrn, Falcon), and then washed 
three times in IMDM medium. Cells were diluted I:20 in 2% acetic 
acid to lyse nonnucleated mature erythrocytes, and then the remaining 
cells were counted. Cells from each fetal liver were plated in triplicate 
in a-methylcellulose~without growth factor or supplemented with EPO 
(3 U/ml) or a cocktail of growth factors (3 U/ml EPO and 1% pokeweed 
mitogen-stimulated murine spleen cell conditioned medium) (Stem- 
Ceil Technologies, Incorporated). Colony formation was monitored at 
appropriate times (2-3 days for CFU-E and 7-l 0 days for BFU-E), and 
benzidine-positive colonies were counted. For retroviral infection, fetal 
liver cells were resuspended in medium containing a recombinant 
spleen focus-forming virus expressing EpoR (SFFVEpoR) (Pharr et 
al., 1993), 4 wglml Polybrene and kept on ice for 2-3 hr. Following 
infection, cells were washed once and plated in a-methylcellulose as 
described above. 
Treatment of Mice with rmEP0 
Pregnant Epo+‘- females, 6-8 weeks old, were injected subcutaneously 
every day for a total of 8 days with 3000 U/kg rmEP0 (in phosphate- 
buffered saline containing 0.025% bovine serum albumin, provided 
by Amgen, Incorporated). Blood for hematocrit.determinations was 
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collected directly into hematocrit tubes (Baxter) from the retroorbital 
sinus under anesthesia. Baseline hematocrit determinations were per- 
formed prior to the first injection. 
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